Seattle Genetics And Genentech Extend ADC Platform Deal
This article was originally published in The Pink Sheet Daily
Platform has delivered more than $130 million in upfronts and milestones to date, with about $2.7 billion in biobucks outstanding.
You may also be interested in...
Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.